Think Tank Live: Collaborative Insights to Solve the Puzzle of Bladder Cancer
Think Tank Live: Collaborative Insights to Solve the Puzzle of Bladder Cancer
February 14, 2025
06:00 PM - 08:00 PM PST
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
Advancements in GU Cancers: Key Data from AUA 2024
Advancements in GU Cancers: Key Data from AUA 2024
Treatment of OAB and the Managed Care Professional: Balancing the Double-Edged Sword
Treatment of OAB and the Managed Care Professional: Balancing the Double-Edged Sword
